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Abstract
A20 is a zinc finger protein that renders cells resistant to apoptosis. However, the recent demonstration that A20-deficient mice
develop severe inflammation and are hyper-responsive to LPS suggests that A20 may play a key role in regulating the inflammatory
response. This study, for the first time, explores the likely mechanism by which A20 can regulate the pro-inflammatory effects of
LPS. More specifically it characterises the ability of A20 to modulate TLR-4 signalling since TLR-4 acts as the signalling receptor
system for LPS. Full length A20 inhibited the ability of TLR-4 to activate the transcription factors, NF-jB and AP-1, and induce
the chemokine IL-8. The inhibitory capacity of A20 on NF-jB was localised to the C-terminal zinc finger domain of A20 whereas
full length A20 was required to effect inhibition of AP-1 and IL-8. Furthermore full length and C-terminal A20 showed similar
regulatory effects on MEKK-1 activation of NF-jB and AP-1 and induction of IL-8. The findings increase our mechanistic un-
derstanding of the anti-inflammatory effects of A20 and suggest that it modulates TLR-4 signalling at or downstream of MEKK-1.
 2003 Elsevier Science (USA). All rights reserved.
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A20 is a novel 90 kDa zinc finger protein that is in-
duced by a range of stimuli including IL-1, TNF, CD40,
and LMP-1 [1–3]. The induction of A20 by these stimuli
tends to render cells resistant to apoptosis [2,3]. The
transcription factor NF-jB is activated by all of these
agents and plays a key role in regulating the expression
of A20 [1–4]. Interestingly A20 in turn acts to inhibit
activation of NF-jB and this serves as an auto-regula-
tory negative feedback system [5]. Since NF-jB regu-
lates the expression of a plethora of pro-inflammatory
genes much interest has focussed on the mechanisms by
which A20 inhibits its activation by IL-1 and TNF. The
C-terminal region of A20 contains seven Cys2/Cys2 zinc
fingers and this region is responsible for effecting inhi-
bition of NF-jB [6–8]. Whilst the mechanism underlying
such inhibitory activity is incompletely understood, the
C-terminal zinc finger domain is known to associate
with A20-binding inhibitor of NF-jB (ABIN)-1 and -2
[9,10]. Both ABIN proteins can mimic the inhibitory
effects of A20 on NF-jB suggesting that they might
mediate the inhibitory effects of A20. Furthermore the
C-terminal region of A20 also interacts with NEMO
(IjB kinase (IKK) c) [11]. Since the latter is a key
scaffolding protein in the IKK complex, that promotes
activation of NF-jB, the interaction of the C-terminal
domain of A20 with NEMO may represent another
important association in mediating the inhibitory effects
of A20 on NF-jB. The N-terminal region of A20 also
interacts with other signalling components in the NF-jB
pathway. Thus A20, through its N-terminal domain, can
directly interact with TNF-receptor-associated factors
(TRAF)-1, TRAF-2 [8], and TRAF-6 [7]. However the
latter report demonstrated that a truncated form of A20,
lacking the N-terminal TRAF-interacting domain, re-
tained the ability to inhibit IL-1 and TNF activation of
NF-jB. This suggests that TRAF binding is not neces-
sary for mediating the inhibitory effects of A20 on
NF-jB.
A20 is also known to inhibit the activation of the
transcription factor AP-1 [5]. However the regions of
A20 that mediate such inhibition have yet to be delin-
eated. The dualist role of A20 in inhibiting both NF-jB
and AP-1 suggests that it may target a signalling com-
ponent that promotes activation of both transcription
factors. One such molecule may be MEKK-1 since it is
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known to mediate activation of both NF-jB and AP-1
[12–14] and a recent report has suggested that A20 in-
hibits MEKK-1 activation of NF-jB [15]. However the
ability of A20 to inhibit MEKK-1 activation of AP-1
was not addressed.
The induction of A20 confers on NF-jB the ability
to regulate its own activation and since NF-jB is a
pivotal player in the generation of the inflammatory
response, A20 is likely to be an endogenous regulator of
inflammation. This has recently been confirmed by a
study showing that A20-deficient mice develop severe
inflammation due to persistent activation of NF-jB
[16]. Furthermore these mice are hyper-responsive to
LPS suggesting that A20 has the capacity to regulate
the inflammatory response to gram-negative bacteria.
However the mechanism by which A20 modulates LPS
responsiveness was not addressed. Toll-like receptor 4
(TLR-4) acts as the receptor for LPS in gram-negative
bacteria and in doing so effects the induction of pro-
inflammatory proteins [17–19]. TLR-4 employs many of
the same signalling components as the IL-1 receptor
system and like IL-1 can activate NF-jB and AP-1 [20].
Since A20 is known to regulate the activation of these
transcription factors by IL-1 we sought to examine the
ability of A20 to inhibit TLR-4 activation of NF-jB
and AP-1 with a view to increasing our understanding
of the anti-inflammatory effects of A20. We also aimed
to identify the regions of A20 that are responsible for
mediating its anti-inflammatory effects. We show that
A20 inhibits the ability of TLR-4 to activate NF-jB
and AP-1 and that the C-terminal zinc finger domain of
A20 retains the ability to inhibit TLR-4 activation of
NF-jB. However the C-terminal domain is ineffective
in regulating activation of AP-1 by TLR-4 and fails to
mimic the inhibitory effects of full length A20 on TLR-
4 induction of IL-8. Finally we present data in which
A20 may target MEKK-1 in the TLR-4 signalling
pathway.
Materials and methods
Materials. HEK293 cells were obtained from European Collection
of Animal Cell Cultures (Salisbury, UK). DMEM, penicillin, strep-
tomycin, trypsin, and foetal calf serum were from Gibco (Grand Is-
land, NY, USA). The Reporter Lysis Buffer, Luciferase Assay System,
and Pfu were from Promega Corporation (WI, USA). EcoRI, XbaI,
and T4 ligase were from New England Biolabs (Hertfordshire, UK).
TOP10 chemically competent Escherichia coli, the plasmid encoding
the dominant positive mutant of MEKK-1 (pFC-MEKK-1), and the
AP-1-luciferase plasmid (AP-1-luc) were obtained from Stratagene (La
Jolla, CA 92037). The NF-jB-luciferase reporter plasmid (jB-luc)
consists of five copies of the NF-jB consensus site cloned into the
luciferase reporter construct pGL3-Basic (Promega). pcDNA3.1 was
obtained from Invitrogen (Groningen, The Netherlands). P3xFLAG-
Myc-CMV was from Sigma (Poole, UK). Polyfect transfection agent
was from Qiagen (West Sussex, UK). Matched antibody pairs against
IL-8 and recombinant human IL-8 (standard) were from R&D
Systems Europe (Abingdon, Oxford, UK). CD4-TLR4 cDNA,
A20pJDM, and the rabbit anti-human A20 antibody were gifts from
Dr. Charles A. Janeway, Jr. (Yale University, USA), Dr. Dermot
Walls (Dublin City University, Ireland), and V.M. Dixit (Genentech,
USA), respectively.
Cell culture. HEK293 cells were cultured in DMEM containing
10% (v/v) foetal calf serum, glutamine (2mM), penicillin (100U/ml),
and streptomycin (100lg=ml). The cells were incubated at 37 C in an
atmosphere of 5% CO2. Cells were passaged using 0.25% (w/v) trypsin
in DMEM.
Cloning of C-terminal domain of A20. The 1251bp fragment of the
gene encoding all seven zinc finger domains of the C-terminal domain
of A20 was amplified from the A20pJDM template using Pfu poly-
merase in a polymerase chain reaction. The forward and reverse
primers contained EcoRI and XbaI sites, respectively. The sequence of
the primers were:
Forward primer: 50-CAT GGA ATT CAG CTT CCG TGC CCC
AGC TT-30
Reverse primer: 50-CTA GTC TAG CAT ACA TCT GCT TGA
ACT GAA A-30
The reaction was initially heated to 94 C for 3min and then sub-
jected to 25 cycles of the following sequential steps: 94 C for 1min,
65 C for 1min, and 72 C for 5min. The products were subjected to
agarose electrophoresis and the 1251 bp fragment excised and purified
using glass wool. The purified PCR fragment and the p3XFLAG-
Myc-CMV expression vector were both digested with EcoRI (10U)
and XbaI (10U) to produce the cohesive ends necessary for ligation.
The reaction mixtures were heated to 65 C for 20min to inactivate
both enzymes. The digested C-terminal A20 fragment was precipi-
tated from solution and the digested vector was purified using the
Qiagen gel extraction kit according to the manufacturers instruc-
tions. A ligation reaction was set up using a 5:1 ratio of insert to
vector and T4 ligase enzyme (3U). The reaction was incubated
overnight at 4 C and the ligation mix was then used to transform
TOP10 chemically competent E. coli. Plasmid DNA was generated
and the presence of the C-terminal A20 insert was confirmed by PCR
using conditions as described above. Plasmid DNA containing the
insert was then subjected to commercial sequence analysis at GATC
GmbH sequencing laboratories.
Transfection of HEK293 cells. HEK293 cells were seeded at
3 105 cells/ml (3ml) in complete DMEM in 6-well tissue culture
dishes and grown for 24 h. Transfections were performed with the
designated amounts of the appropriate plasmids using Polyfect trans-
fection reagent (Qiagen) according to the manufacturers recommen-
dations. The plasmids included: NF-jB-regulated luciferase reporter
(0:5lg), AP-1 regulated luciferase reporter (0:5lg), CD4/TLR4 (1lg),
MEKK-1 (50–200 ng), A20pJDM (1lg), and C-terminal A20-
p3xFLAG-Myc-CMV (1lg). The total amount of DNA in each
transfection was 3:6lg and pcDNA3.1(+) was used to supplement the
total DNA to this level. Cells were allowed to recover for 24 h after the
transfection and the medium was removed and replaced with complete
DMEM. The cells were then allowed to grow for another 6 h. Con-
ditioned medium was retained for IL-8 measurement (see below). Cell
extracts were generated and measured for luciferase activity using the
Luciferase Assay System with Reporter Lysis Buffer from Promega
Corporation. Extracts were also assayed for protein content [21] and
these values were used for normalising luciferase readings.
Western immunoblotting of transfected cells. HEK293 cells were
electroporated as above with A20pJDM or C-terminal A20-
p3xFLAG-Myc-CMV. The cells were then grown for 24 h. The 6-well
dishes were then placed on ice, the medium removed, and the cells
washed twice with ice-cold PBS (1ml). The cells were then incubated
for 30min in ice-cold lysis buffer (250ll) (20mM Tris–HCl buffer, pH
7.5, containing 150mM NaCl, 1% (v/v) Triton, 1mM EDTA, 1mM
Na3VO4, 1mM DTT, 1mM PMSF, and 1mM of protease inhibitor
mix of leupeptin, aprotonin, benzamidine, and trypsin inhibitor). Cells
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were scraped and pelleted by centrifugation at 12,000g for 10min at
4 C. The resulting supernatants were retained and their protein con-
tent was measured as above. Samples (30lg protein) were then mixed
with SDS–PAGE sample buffer (50mM Tris–HCl buffer, pH 6.8
containing 2% (w/v) SDS, 10% (w/v) glycerol, 1% (v/v) 2-mercap-
toethanol, and 0.1% (w/v) bromophenol blue) and heated to 90 C for
5min. Lysates were cleared of particulate material by centrifugation at
20,000g for 5min. The clear supernatants were subjected to SDS–
PAGE on 10% polyacrylamide slab gels and the separated proteins
electrophoretically transferred from the gels to nitrocellulose. The
presence of full length and C-terminal A20 expression was detected by
probing the nitrocellulose with a rabbit anti-human A20 polyclonal
antibody (1/500 dilution) and visualising using a horseradish peroxi-
dase-conjugated donkey anti-rabbit antibody in conjunction with an
enhanced chemiluminescence system (Pierce) according to the manu-
facturers instructions.
Assays of IL-8. Conditioned medium from cells (see above) was
assayed for IL-8 using a standard ‘‘sandwich type’’ ELISA. The
ELISA assay utilised matched antibody pairs and recombinant human
IL-8 as standard and was performed according to the manufacturers
instructions (R&D Systems).
Statistical analysis. Significance was evaluated by Students t test
for paired data.
Results
Full length A20 inhibits TLR-4 activation of NF -jB and
AP-1 and induction of IL-8
The hyper-responsive nature of A20-deficient mice to
LPS coupled to their susceptibility to develop severe
inflammation emphasises the anti-inflammatory poten-
tial of A20. In order to explore the molecular mecha-
nism underlying the regulatory effects of A20 on LPS
and inflammation, the present study initially examined
the ability of A20 to modulate the activation of the
transcription factors, NF-jB and AP-1, by TLR-4.
HEK293 cells were thus co-transfected with CD4/TLR4,
the constitutively active form of TLR4 [17], in the ab-
sence and presence of A20pJDM, a mammalian ex-
pression construct that constitutively expresses full
length A20. The overexpression of A20 was confirmed
by the presence of a 90 kDa band that was reactive with
a rabbit anti-human A20 polyclonal antibody in western
immunoblotting analysis of extracts from transfected
cell populations (Fig. 1A). The lack of detectable A20 in
HEK293 cells that had not been transfected with
A20pJDM indicates low or absent basal expression of
A20 in these cells. The overexpressed A20 was initially
examined for its ability to regulate CD4/TLR4 activa-
tion of NF-jB (Fig. 1B). The activity of the latter was
determined by measuring the induction of a transfected
NF-jB-regulated luciferase gene (jB-luc). The luciferase
expression was induced 6-fold when cells were co-
transfected with CD4/TLR4. However, the overexpres-
sion of full length A20 was sufficient to abolish the CD4/
TLR4 induction of luciferase. A20 was next assessed for
its capacity to modulate activation of AP-1 by TLR-4
(Fig. 1C). The activity of AP-1 was determined by
measuring the expression of a transfected AP-1 lucifer-
ase construct (AP-1-luc). The cells that were transfected
with CD4/TLR-4 showed a 5-fold induction of AP-1
regulated luciferase relative to a basal expression.
However, like NF-jB, the expression of the AP-1-reg-
ulated luciferase by CD4/TLR4 was completely abro-
Fig. 1. Effects of full length A20 on TLR-4 signalling. (A) HEK293
cells were transfected with pcDNA3.1(+) or A20pJDM (1lg). Cell
lysates were subsequently subjected to SDS–PAGE on a 10% poly-
acrylamide gel and electroblotted onto nitrocellulose membrane. The
presence of full length A20 expression was detected by probing the
nitrocellulose with a rabbit anti-human A20 polyclonal antibody (1/
500 dilution) and visualising by enhanced chemiluminescence. (B,C)
HEK293 cells were co-transfected with or without CD4/TLR4 (1lg) in
the presence or absence of A20pJDM (1lg) and (B) jB-luc (0:5lg) or
(C) AP-1-luc (0:5lg). Cell extracts were subsequently measured for
luciferase activity and protein content. Data are presented relative to
cells transfected in the absence of CD4/TLR4 (D) HEK293 cells were
co-transfected with or without CD4/TLR4 (1lg) in the presence or
absence of A20pJDM (1lg). Conditioned medium from cells was then
assayed for IL-8 by ELISA. Results represent meansSEM of three
independent experiments (*, p < 0:05; **, p < 0:01).
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gated when cells were co-transfected with A20pJDM.
Thus A20 is a very effective inhibitor of TLR-4 activa-
tion of NF-jB and AP-1. In order to appreciate the
functional relevance of the inhibitory effects on A20 on
TLR-4 activation of NF-jB and AP-1 we examined the
effects of A20 on the ability of TLR-4 to induce IL-8
(Fig. 1D). The transfection of HEK293 cells with CD4/
TLR4 was sufficient to effect a 6-fold induction of IL-8.
However, the overexpression of full length A20 abol-
ished this induction again emphasising the anti-inflam-
matory effects of A20.
C-terminal zinc finger domain of A20 inhibits TLR-4
activation of NF -jB but not AP-1
We then sought to identify the regions of A20 that
mediate the above regulatory effects on TLR-4 sig-
nalling. It was already known that the C-terminal zinc
finger domain of A20 is sufficient to inhibit IL-1 ac-
tivation of NF-jB. The present study thus explored
the ability of C-terminal A20 to mimic full length A20
in its abolition of TLR-4 activation of NF-jB. Fur-
thermore there was no existing data on the ability of
C-terminal domain to regulate AP-1 activation by any
stimuli and thus this novel aspect was also addressed
in the present project. The region of the A20 gene
encoding all seven zinc finger domains of the C-ter-
minal domain of A20 was thus amplified by PCR and
subcloned into the mammalian expression vector
p3xFLAG-Myc-CMV. The resulting construct was
used to overexpress the C-terminal region of A20 in
HEK293 cells. The overexpression of the truncated
A20 was evident by the presence of a 48 kDa band
that reacted with the same rabbit anti-human A20
polyclonal antibody as used above (Fig. 2A). The ex-
pression vector encoding the C-terminal domain of
A20 was thus used to probe the ability of this region
of A20 to regulate TLR-4 activation of NF-jB and
AP-1. The overexpression of C-terminal A20 caused
significant inhibition of TLR-4 activation of NF-jB
(Fig. 2B). However, unlike full length A20 the inhibi-
tion was incomplete. Furthermore the C-terminal re-
gion of A20 failed to mimic full length A20 in that it
failed to show any modulatory effects on TLR-4 acti-
vation of AP-1 (Fig. 2C). Thus whilst the C-terminal
region of A20 is sufficient to inhibit TLR-4 activation
of NF-jB, full length A20 is required to manifest in-
hibition of TLR-4 activation of AP-1. The C-terminal
zinc finger domain of A20 was also assessed for its
capacity to modulate TLR-4 induction of IL-8 in order
to assess the consequence of its inability to regulate
AP-1 on its anti-inflammatory potential (Fig. 2D). The
C-terminal domain was ineffective in modulating IL-8
induction by TLR-4 suggesting that the ability of full
length A20 to inhibit AP-1 is a key component in
mediating its anti-inflammatory activity.
Fig. 2. Effects of C-terminal A20 on TLR-4 signalling. (A) HEK293
cells were transfected with pcDNA3.1(+) or C-terminal A20-
p3xFLAG-Myc-CMV (1lg). Cell lysates were subsequently subjected
to SDS–PAGE on a 10% polyacrylamide gel and electroblotted onto
nitrocellulose membrane. The presence of C-terminal A20 expression
was detected by probing the nitrocellulose with a rabbit anti-human
A20 polyclonal antibody (1/500 dilution) and visualising by enhanced
chemiluminescence. (B,C) HEK293 cells were co-transfected with or
without CD4/TLR4 (1lg) in the presence or absence of C-terminal
A20-p3xFLAG-Myc-CMV(1lg) and (B) jB-luc (0:5lg) or (C) AP-1-
luc (0:5lg). Cell extracts were subsequently measured for luciferase
activity and protein content. Data are presented relative to cells
transfected in the absence of CD4/TLR4. (D) HEK293 cells were co-
transfected with or without CD4/TLR4 (1lg) in the presence or ab-
sence of C-terminal A20-p3xFLAG-Myc-CMV (1lg). Conditioned
medium from cells was then assayed for IL-8 by ELISA. Results rep-
resent meansSEM of three independent experiments (*, p < 0:05).
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Full length A20 inhibits MEKK-1 activation of NF -jB
and AP-1 and induction of IL-8
We next attempted to identify a target for A20 in
mediating its inhibitory effects on TLR-4. MEKK-1 was
selected as a lead candidate since it is known to regulate
activation of both NF-jB and AP-1. Full length A20
was thus assessed for its ability to regulate MEKK-1
activation of NF-jB and AP-1 and induction of IL-8 in
HEK293 cells (Fig. 3). A plasmid encoding a dominant
positive form of MEKK-1, when co-transfected with the
jB-luc and AP-1-luc constructs, caused a 6-fold and
140-fold induction of luciferase, respectively. The over-
expression of full length A20 caused a total abolition of
the induction of jB-luc (Fig. 3A) and a partial inhibition
of AP-1-luc (Fig. 3B). The regulatory effects of full
length A20 on MEKK-1 induction of IL-8 was also
assessed (Fig. 3C). The transfection of HEK293 cells
with MEKK-1 was sufficient to effect a 12-fold induc-
tion of IL-8. However the overexpression of full length
A20 reduced this induction. Thus the inhibitory effects
of A20 on MEKK-1 activation of NF-jB and AP-1 and
induction of IL-8 mimicked its effects on TLR-4 sug-
gesting that A20 inhibits TLR-4 at or downstream of
MEKK-1.
C-terminal zinc finger domain of A20 inhibits MEKK-1
activation of NF -jB but not AP-1
In a scenario where A20 inhibits TLR-4 at or
downstream of MEKK-1, one would predict that the
C-terminal region of A20 should also regulate MEKK-
1 in a manner similar to its modulation of TLR-4. This
was thus explored by examining the effects of the
Fig. 3. Effects of full length A20 on MEKK-1 signalling. (A,B)
HEK293 cells were co-transfected with or without MEKK-1 (200 ng
in (A); 50 ng in (B)) in the presence or absence of A20pJDM (1lg)
and (A) jB-luc (0:5lg) or (B) AP-1-luc (0:5lg). Cell extracts were
subsequently measured for luciferase activity and protein content.
Data are presented relative to cells transfected in the absence of
MEKK-1. (C) HEK293 cells were co-transfected with or without
MEKK-1 (200 ng) in the presence or absence of A20pJDM (1lg).
Conditioned medium from cells was then assayed for IL-8 by ELISA.
Results represent meansSEM of three independent experiments
(*, p < 0:05).
Fig. 4. Effects of C-terminal A20 on MEKK-1 signalling. (A,B)
HEK293 cells were co-transfected with or without MEKK-1 (200 ng in
(A); 50 ng in (B)) in the presence or absence of C-terminal A20-
p3xFLAG-Myc-CMV (1lg) and (A) jB-luc (0:5lg) or (B) AP-1-luc
(0:5lg). Cell extracts were subsequently measured for luciferase activity
and protein content. Data are presented relative to cells transfected in
the absence of MEKK-1. (C) HEK293 cells were co-transfected with or
without MEKK-1 (200 ng) in the presence or absence of C-terminal
A20-p3xFLAG-Myc-CMV (1lg). Conditioned medium from cells was
then assayed for IL-8 by ELISA. Results represent means SEM of
three independent experiments (*, p < 0:05).
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C-terminal region of A20 on MEKK-1 activation of
NF-jB and AP-1 and induction of IL-8 (Fig. 4). The
overexpression of C-terminal A20 was sufficient to
strongly inhibit MEKK-1 activation of NF-jB (Fig.
4A). However C-terminal A20 was ineffective in regu-
lating the MEKK-1 activation of AP-1 (Fig. 4B) and
also had no regulatory effects on MEKK-1 induction of
IL-8 (Fig. 4C). Again the analogous effects of C-ter-
minal A20 on both TLR-4 and MEKK-1 signalling
provide support for A20 regulating TLR-4 activity at
or downstream of MEKK-1.
Discussion
The tendency of A20-deficient mice to develop severe
inflammation [16] coupled to their hyper-responsive
nature to LPS suggests that A20 may act as an endog-
enous regulatory system in controlling the inflammatory
response to gram-negative bacteria. This is further
supported by the ability of LPS to increase the expres-
sion of A20 in endothelial cells [1]. The present study
thus directly explored the ability of A20 to regulate the
LPS signalling pathway with a view to increasing our
mechanistic understanding of the anti-inflammatory ef-
fects of A20.
TLR-4 acts as the signalling receptor system for LPS
and thus in order to examine the effects of A20 on LPS
the influence of A20 on TLR-4 signalling was directly
addressed. The study exploited CD4/TLR4, the consti-
tutively active form of TLR-4 [17]. Full length A20 was
initially shown to abolish TLR-4 activation of NF-jB.
This mirrors the previously described inhibitory effects
of A20 on IL-1 and TNF activation of NF-jB [5]. Thus
the present study demonstrates that A20 may be a uni-
versal inhibitor of the signalling pathways of key pro-
inflammatory stimuli. However the inhibitory effects of
A20 on LPS is not limited to blockade of NF-jB. This
study also shows that A20 is an effective inhibitor of AP-
1 activation by TLR-4. Since NF-jB and AP-1 are key
transcription factors in promoting the expression of a
plethora of pro-inflammatory proteins the study subse-
quently examined the modulatory effects of A20 on IL-8
expression by TLR-4. IL-8 was chosen as a typical pro-
inflammatory protein since it is prominently induced by
LPS and plays a key role in promoting leukocyte re-
cruitment into tissue during the inflammatory response
[22]. Furthermore NF-jB and AP-1 are known to play
key roles in regulating the expression of IL-8 [23] and it
therefore allowed for a definition of the functional
consequence of the inhibitory effects of A20 on the two
transcription factors. A20 proved to be a powerful in-
hibitor of TLR-4 induction of IL-8. Such inhibitory ef-
fects of A20 on TLR-4 activation of NF-jB and AP-1
and induction of IL-8 are likely to underlie the anti-in-
flammatory potential of A20 and form a plausible basis
for explaining the hyper-responsive nature of A20-defi-
cient mice to LPS.
It was previously known that the C-terminal zinc
finger domain confers on A20 its ability to inhibit IL-1
activation of NF-jB [6–8]. This study demonstrated that
the C-terminal regions of A20 is also sufficient to cause
significant inhibition of TLR-4 activation of NF-jB.
This study for the first time also examined the ability of
the C-terminal region of A20 to modulate activation of
AP-1. The C-terminal region was shown to be ineffective
in regulating TLR-4 activation of AP-1. Thus A20
demonstrates different structural requirements in its in-
hibition of NF-jB and AP-1. The C-terminal region is
sufficient to inhibit NF-jB but ineffective in regulating
AP-1. The N-terminal region appears to be required for
manifesting the latter and this may be related to the
ability of the N-terminal region to bind to signalling
molecules in the TLR-4 pathway. It is interesting to note
that the N-terminal region of A20 has been shown to
associate with TRAF-6 [7], a key signalling molecule in
the TLR-4 pathway.
Interestingly C-terminal A20 failed to affect the
ability of TLR-4 to induce IL-8. This may be due to its
ineffectiveness in regulating AP-1. Nevertheless it is
somewhat surprising considering that C-terminal A20
acted as an effective inhibitor of NF-jB. However whilst
the inhibitory effects of C-terminal A20 on TLR-4 ac-
tivation of NF-jB were strong, the inhibition was in-
complete and thus the residual NF-jB may be sufficient
to co-operate with AP-1 in promoting IL-8 expression.
Overall the studies show that the C-terminal region of
A20 does not possess the same anti-inflammatory
properties of the full length protein.
The possible target for A20 in its inhibition of TLR-4
signalling was next addressed. MEKK-1 was chosen as
a lead candidate since it is known to regulate activation
of both NF-jB and AP-1 [12–14] and a recent report
had shown that A20 could inhibit MEKK-1 signalling
at least with respect to NF-jB [15]. The present study
confirms that A20 inhibits MEKK-1 activation of
NF-jB and also for the first time shows that A20 in-
hibits MEKK-1 activation of AP-1. The similar effects
of A20 on TLR-4 and MEKK-1 activation of NF-jB
and AP-1 provides support for a model that A20 may
regulate TLR-4 signalling at or downstream of MEKK-
1. However it is worth noting that the inhibition by A20
of MEKK-1 activation of AP-1 is partial unlike the
total blockade of TLR-4 activation of AP-1. This may
be due to the considerably more powerful stimulus
provided by overexpression of MEKK-1 relative to
CD4/TLR4. Furthermore the partial inhibition of
MEKK-1 activation of AP-1 is also likely to explain
the incomplete inhibitory effects of A20 on MEKK-1
induction of IL-8.
In order to further confirm that MEKK-1 is the likely
target for A20 in the TLR-4 pathway the C-terminal
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zinc finger domain of A20 was also assessed for its
regulatory effects on MEKK-1. C-terminal A20 regu-
lated MEKK-1 signalling in a similar manner to its ef-
fects on TLR-4 signalling in that it inhibited MEKK-1
activation of NF-jB but was without effect on activation
of AP-1 and induction of IL-8. The analogous effects of
C-terminal A20 on TLR-4 and MEKK-1 signalling
again supports MEKK-1 signalling as a likely target for
A20 in the TLR-4 pathway.
The C-terminal A20 domain shares with full length
A20 its ability to inhibit NF-jB but fails to replicate the
inhibitory effects on AP-1. This suggests that the N-
terminal domain of A20 is required for manifesting its
inhibitory effects on AP-1 but is redundant for its reg-
ulation of NF-jB. This may be due to the ability of the
N-terminal and C-terminal domains to interact with
different signalling proteins. Thus the N-terminal do-
main is known to interact with TRAF proteins [7,8]
whereas the C-terminal region interacts with NEMO
[11]. Since the latter is involved in promoting activation
of NF-jB but not AP-1, the interaction of C-terminal
A20 with NEMO may explain its inhibition of NF-jB
but not AP-1. In contrast the interaction of the N-ter-
minal domain of A20 with the TRAF proteins may be
required for effecting inhibition of AP-1.
In summary this study demonstrates for the first
time that the anti-inflammatory and regulatory effects
of A20 on TLR-4 may be mediated by regulating
MEKK-1 activation of NF-jB and AP-1. Furthermore
it also defines different structural requirements of A20
for inhibiting the two transcription factors. This is of
value in increasing our mechanistic understanding of
the anti-inflammatory effects of A20. A full apprecia-
tion of the mechanism(s) may help in the therapeutic
exploitation of A20 as a novel anti-inflammatory
strategy.
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